US Multiple Myeloma Therapeutics Market Report 2022-2030

US Multiple Myeloma Therapeutics Market Analysis

$ 3999

The US Multiple Myeloma Therapeutics Market was valued at $3.5 Bn in 2022 and is estimated to expand at a CAGR of 2.5% from 2022 to 2030 and will reach $4.26 Bn in 2030. One of the main reasons propelling the growth of this Market is advancements in therapeutic development and increased funding for research and development. The market is segmented by type, drug, and distribution channel. Some key players in this Market are Takeda Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, Amgen, AbbVie, Novartis, GlaxoSmithKline, Sanofi and others.

ID: IN10USPH301 CATEGORY: Rare Diseases GEOGRAPHY: US AUTHOR: Nandini Shah

Buy Now

US Multiple Myeloma Therapeutics Market Executive Summary

The US Multiple Myeloma Therapeutics Market was valued at $3.5 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 2.5% from 2022 to 2030 and will reach $4.26 Bn in 2030. Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections. The US multiple myeloma therapeutics market is a growing market due to the increasing prevalence of multiple myeloma and the development of new therapies. The growth of the market is driven by factors such as an aging population, increasing prevalence of multiple myeloma, and advancements in the development of new therapies. The introduction of new therapies such as immunomodulatory drugs (IMiDs) and proteasome inhibitors has revolutionized the treatment of multiple myeloma.

US Multiple Myeloma Therapeutics Market

Market Dynamics

Market Growth Drivers

he incidence of multiple myeloma has been increasing in the US due to the aging population, with an estimated 32,270 new cases and 12,830 deaths expected in 2022. This increase in prevalence is driving the demand for multiple myeloma therapies. The development of new therapies, such as immunomodulatory drugs (IMiDs), proteasome inhibitors, and monoclonal antibodies, has significantly improved the treatment of multiple myeloma. The development of these therapies has been a major driver of the market growth. As awareness of multiple myeloma increases, more patients are being diagnosed at earlier stages, leading to a higher demand for therapies. According to the American Cancer Society, the five-year survival rate for multiple myeloma patients has increased from 34% in the 1970s to 54% in recent years, indicating the growing effectiveness of therapies and increased awareness of the disease. Funding for research and development of new therapies has increased significantly in recent years, with the National Cancer Institute (NCI) investing $255 Mn in multiple myeloma research in 2020. This funding has led to the development of new therapies and is expected to drive market growth in the coming years.

Market Restraints

The cost of multiple myeloma therapies is high, and the cost of newer therapies such as monoclonal antibodies and CAR T-cell therapy is even higher. This limits the affordability of these therapies for many patients, leading to barriers in access to treatment. The treatment of multiple myeloma is complex and often requires a combination of therapies, including chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies. This complexity can lead to challenges in treatment planning and management, as well as potential side effects and complications. Many multiple myeloma therapies have adverse side effects, including anemia, fatigue, neuropathy, and gastrointestinal problems. These side effects can impact the quality of life for patients and limit the effectiveness of therapies. Despite significant advancements in the development of new therapies, some patients may not respond to treatment or may develop resistance to therapies. This limits the efficacy of existing therapies and highlights the need for continued research and development of new treatments. The US multiple myeloma therapeutics market is highly regulated, with strict requirements for drug approval and pricing. This can lead to delays in the approval of new therapies and challenges in pricing and reimbursement for existing therapies.

Competitive Landscape

Key Players

Takeda Pharmaceuticals
Bristol Myers Squibb
Johnson & Johnson
Amgen
AbbVie
Novartis
GlaxoSmithKline
Sanofi
Karyopharm Therapeutics
Celgene: Celgene, a subsidiary of Bristol Myers Squibb, is a biopharmaceutical company that develops and markets multiple myeloma therapies, including Revlimid and Pomalyst.

Healthcare Policies and Regulatory Landscape

Regulatory and healthcare policies in the US multiple myeloma therapeutics market are crucial for ensuring patient safety and access to effective therapies. The US Food and Drug Administration (FDA) regulates the approval of multiple myeloma therapies, including new drug applications and biologics license applications. The FDA ensures that therapies meet safety and efficacy standards before they are approved for use in the US market.

Affordable Care Act (ACA) is a federal law that aims to improve access to healthcare for Americans. The law includes provisions for coverage of cancer treatments, including multiple myeloma therapies, and provides financial assistance to eligible patients.

The Orphan Drug Act provides incentives for the development of therapies for rare diseases, including multiple myeloma. These incentives include tax credits, research grants, and marketing exclusivity.

Reimbursement Scenario

Reimbursement for multiple myeloma therapies in the US is complex and can vary depending on the type of therapy, insurance coverage, and treatment setting.

Most multiple myeloma therapies are covered by insurance, including Medicare and Medicaid. However, coverage may vary depending on the patient's insurance plan, the therapy being used, and the treatment setting. The reimbursement for multiple myeloma therapies can vary depending on the treatment setting. For example, therapies administered in a hospital setting may have different reimbursement rates than those administered in a physician's office.

Medicare Part B Coverage: Medicare Part B covers certain multiple myeloma therapies, including chemotherapy, immunotherapy, and supportive care drugs. The reimbursement rates for these therapies are set by the Medicare program.

Medicaid Coverage: Medicaid provides coverage for multiple myeloma therapies for eligible patients, although coverage may vary by state.

Reimbursement for CAR T-cell Therapy: CAR T-cell therapy is a newer and more expensive therapy for multiple myeloma.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Multiple Myeloma Therapeutics Market Segmentation

By Treatment

Chemotherapy
Immunotherapy
Targeted therapy
Radiation therapy
Stem cell transplant

By Distribution Channel

Hospitals
Retail
Online

By End User (Revenue, USD Bn):

Hospitals
Clinics
Cancer Research Centers

By Drug Class

Immunomodulatory drugs (IMiDs)

One of the most common therapies used to treat myeloma are immunomodulatory drugs, or IMiDs. These drugs work by modifying the immune system to attack myeloma cells and have been a significant advance in the treatment of multiple myeloma. Some of the commonly used IMiDs in multiple myeloma include:

Lenalidomide (Revlimid): Lenalidomide is an oral medication that is used in the treatment of multiple myeloma, as well as other blood cancers such as myelodysplastic syndromes (MDS). It may help the immune system in eliminating cancerous or abnormal blood cells. Moreover, it might stop the development of new blood vessels that tumours require to expand.
Pomalidomide (Pomalyst): Pomalidomide is an oral medication that is used to treat multiple myeloma. It works in a similar way to lenalidomide, by enhancing the immune system's ability to target cancer cells. Also, it makes it easier for immune cells to eliminate faulty myeloma cells, aiding in the production of healthy blood cells in the myeloma.
Thalidomide (Thalomid): Thalidomide was the first IMiD to be used in the treatment of multiple myeloma. It works by modulating the immune system and preventing the growth of blood vessels that supply the tumor
CC- 4047 (Actimid): CC-4047 is a newer IMiD that is still under investigation for the treatment of multiple myeloma. It works by inhibiting the growth of cancer cells and promoting their death.

Proteasome inhibitors

Proteasome inhibitors are a class of drugs that are commonly used in the treatment of multiple myeloma. They work by blocking the activity of proteasomes, which are cellular structures that break down proteins. This leads to the accumulation of proteins within the myeloma cells, ultimately causing their death. Some proteasome inhibitors used in multiple myeloma include:

Bortezomib (Velcade): Bortezomib was the first proteasome inhibitor approved for the treatment of multiple myeloma. It is given by injection and is often used in combination with other drugs, such as chemotherapy or immunomodulatory drugs. Bortezomib is highly effective in inducing remissions in newly diagnosed and relapsed/refractory multiple myeloma patients.
Carfilzomib (Kyprolis): Carfilzomib is a newer proteasome inhibitor that is approved for the treatment of multiple myeloma. It is given by injection and can be used as a single agent or in combination with other drugs. Carfilzomib has shown excellent results in heavily pretreated patients with relapsed/refractory multiple myeloma.
Ixazomib (Ninlaro): Ixazomib is an oral proteasome inhibitor that is approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma. It is the first oral proteasome inhibitor and offers the convenience of home administration.

Monoclonal antibodies:

Monoclonal antibodies, target specific proteins on the surface of myeloma cells, causing them to be destroyed by the immune system. Some of the commonly used monoclonal antibodies in multiple myeloma include:

Daratumumab (Darzalex): Daratumumab is a monoclonal antibody that targets a protein called CD38, which is highly expressed on the surface of myeloma cells. By binding to CD38, daratumumab triggers the immune system to attack and destroy the cancer cells. It is approved for use in multiple myeloma in combination with other drugs, such as lenalidomide or bortezomib.
Elotuzumab (Empliciti): Elotuzumab is a monoclonal antibody that targets a protein called SLAMF7, which is also expressed on the surface of myeloma cells. By binding to SLAMF7, elotuzumab enhances the immune system's ability to attack the cancer cells. It is approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.
Isatuximab (Sarclisa): Isatuximab is a monoclonal antibody that targets a protein called CD38, similar to daratumumab. By binding to CD38, isatuximab triggers the immune system to attack and destroy the cancer cells. It is approved for use in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.

Chemotherapy drugs

Chemotherapy drugs work by killing rapidly dividing cells, including cancer cells. Chemotherapy is often used in combination with other drugs, such as steroids, immunomodulatory drugs, or proteasome inhibitors, to improve their effectiveness. Here are some chemotherapy drugs used in multiple myeloma:

Melphalan: Melphalan is an alkylating agent that is commonly used in the treatment of multiple myeloma. It is used as a preventative measure before having a stem cell transplant to treat multiple myeloma. It works by damaging the DNA of cancer cells, leading to their death. Melphalan is often used in combination with other drugs, such as prednisone, to treat newly diagnosed multiple myeloma.
Cyclophosphamide: Cyclophosphamide works by damaging the DNA of cancer cells, leading to their death. Cyclophosphamide is often used in combination with other drugs, such as dexamethasone, to treat relapsed or refractory multiple myeloma. Cyclophosphamide inhibits cancer cell proliferation, causing the body to kill the cancer cells.
Doxorubicin: Doxorubicin works by inhibiting the synthesis of DNA and RNA, leading to the death of cancer cells. Doxorubicin is often used in combination with other drugs, such as bortezomib or dexamethasone, to treat newly diagnosed or relapsed/refractory multiple myeloma. Doxorubicin belongs to the anthracycline class of chemotherapeutic drugs, which also includes daunorubicin, idarubicin, and epirubicin.
Etoposide: Etoposide is a topoisomerase inhibitor chemotherapy drug that is used in the treatment of multiple myeloma. It works by inhibiting the activity of topoisomerase enzymes, which are necessary for DNA replication and repair. Etoposide is often used in combination with other drugs, such as cisplatin, to treat relapsed or refractory multiple myeloma. It works by reducing or preventing cancer cell proliferation in your body.

Steroids

Steroids such as dexamethasone and prednisone are often used in combination with other drugs to treat multiple myeloma. They can reduce inflammation, suppress the immune system, and promote the death of myeloma cells.

Dexamethasone: Dexamethasone works by reducing inflammation and suppressing the immune system. Dexamethasone is often used in combination with other drugs to treat relapsed or refractory multiple myeloma.
Prednisone: Prednisone works by suppressing the immune system and reducing inflammation. Prednisone is often used in combination with other drugs, such as chemotherapy, to treat newly diagnosed multiple myeloma.
Methylprednisolone: Methylprednisolone is a steroid that is similar to prednisone and is also used in the treatment of multiple myeloma. It works by suppressing the immune system and reducing inflammation. Methylprednisolone is often used in combination with other drugs to treat relapsed or refractory multiple myeloma.

Steroids are effective in reducing inflammation and suppressing the immune system, which can help to control the growth of myeloma cells. However, they can have side effects, such as weight gain, mood changes, and increased risk of infection, so their use needs to be carefully monitored.

Others

Other drug classes used to treat multiple myeloma include:

Histone deacetylase inhibitors- A new class of cytostatic drugs that suppress tumour cell proliferation in vitro and in vivo by inducing cell cycle arrest, differentiation, and/or apoptosis
Immune checkpoint inhibitors- Checkpoint proteins are produced by some immune system cells, such as T cells, as well as some cancer cells. These checkpoints prevent too aggressive immune responses and, in some cases, prevent T cells from destroying cancer cells.
Targeted therapies- Proteasome inhibitors are one type of targeted therapy for multiple myeloma. Proteasome inhibitors include bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro). They target proteasomes, which are enzymes that breakdown proteins in cells.

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.